These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36548358)

  • 1. High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya.
    Awandu SS; Ochieng Ochieng A; Onyango B; Magwanga RO; Were P; Atieno Ochung' A; Okumu F; Oloo MA; Katieno JS; Lidechi S; Ogutu F; Awuor D; Kirungu JN; Orata F; Achieng J; Oure B; Nyunja R; Muok EMO; Munga S; Estambale B
    PLoS One; 2022; 17(12):e0272751. PubMed ID: 36548358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
    Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
    Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms.
    Javed W; Abidi SHB; Baqar JB
    BMC Infect Dis; 2022 May; 22(1):481. PubMed ID: 35596145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq.
    Saeed AY; Assafi MS; Othman HE; Shukri HM
    J Infect Dev Ctries; 2022 Jul; 16(7):1126-1130. PubMed ID: 35905016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.
    Almehmadi M; Salih MM; Shafie A; Alsharif A; Alsiwiehr N; El-Askary A; Alzahrani K; Al-Hazmi A; Aljuaid A; Abdulazziz O; Almalki AA; Allahyani M; Eed E; Alharbi AM; Halawi M; Allam HH; Abutawil H; Alosimi E; Gharib AF
    Clin Lab; 2022 Nov; 68(11):. PubMed ID: 36378000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.
    Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F
    Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of SARS-CoV-2 detection methods using stool, blood, and nasopharyngeal swab samples.
    Oloo MA; Awandu SS; Onyango B; Magwanga RO; Oluoch AO; Lidechi S; Muok EM; Munga S; Estambale B
    Pan Afr Med J; 2023; 46():21. PubMed ID: 38107343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the COVID-19 pandemic progression in Ecuador through seroprevalence analysis of anti-SARS-CoV-2 IgG/IgM antibodies in blood donors.
    Gaviria A; Tamayo-Trujillo R; Paz-Cruz E; Cadena-Ullauri S; Guevara-Ramírez P; Ruiz-Pozo VA; Cevallos F; Aguirre-Tello V; Risueño K; Yánez MP; Cabrera-Andrade A; Zambrano AK
    Front Cell Infect Microbiol; 2024; 14():1373450. PubMed ID: 38975325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
    Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
    J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.
    Hansen CB; Dvoncova K; Pérez-Alós L; Fogh K; Madsen JR; Garred CH; Jarlhelt I; Nielsen PB; Petersen SS; Fjordager CG; Lauritsen KT; Hilsted L; Boding L; Iversen KK; Hyveled L; Garred P
    J Intern Med; 2023 Jun; 293(6):763-781. PubMed ID: 37024264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020.
    Ling RJ; Yu YH; He JY; Zhang JX; Xu S; Sun RR; Zhu WC; Chen MF; Li T; Ji HL; Wang HQ
    Biomed Environ Sci; 2021 Sep; 34(9):743-749. PubMed ID: 34530966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
    Hayer J; Urlaub E
    Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
    Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
    Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.